Discover trends, market shifts, and competitive outlooks for the chronic spontaneous urticaria industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What Are the Projected Market Size and Growth Rates for the Chronic Spontaneous Urticaria Market From 2025 To 2029?

In recent years, the market size for chronic spontaneous urticaria has seen robust growth. It is projected to increase from $2.06 billion in 2024 to $2.23 billion in 2025, with a compound annual growth rate (CAGR) of 8.6%. This growth during the historical period can be credited to advancements in diagnostic tools, rising knowledge within healthcare circles, the establishment of patient advocacy and assistance groups, ongoing research and clinical trials testing new treatments, and the increase in healthcare spending.

Expectations are high for significant expansion in the chronic spontaneous urticaria market in the coming years, with predictions for it to escalate to a worth of $3.08 billion by 2029, paced by a compound annual growth rate (CAGR) of 8.4%. The predicted growth within this time frame is largely due to factors such as the rise in the number of confirmed CSU cases, an expanding patient base, enhancements in healthcare infrastructure, a supportive regulatory landscape, and patient-focused treatment approaches, not to mention economic progress in emergent markets. Major anticipated trends during this forecast period encompass technological innovation, progress in biological treatments, tailored medicine, the rise of telemedicine and digital health, advanced diagnostics technologies, the application of AI and machine learning, along with an increase in approved and launched drug treatments.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16651&type=smp

What Are the Core Market Drivers Propelling Growth in the Chronic Spontaneous Urticaria Industry?

The chronic spontaneous urticaria market is predicted to expand due to rising alcohol intake. The increased use of alcohol is linked to a variety of factors, including social customs, stress, marketing, affordability, and accessibility. Drinking alcohol may make chronic spontaneous urticaria symptoms worse for some individuals, leading to additional hives and swelling. As an example, according to rehabs.UK, an organisation based in the UK that provides support and guidance for addiction recovery, in February 2024, 55% of males reported drinking alcohol on a weekly basis, as did 41% of females. In addition, 8% of males said they drank nearly daily, compared to 5% of females. Over the course of 2021 to 2022, there were 342,795 hospital admissions directly related to alcohol, equating to a rate of 626 admissions per 100,000 individuals. As a result, the increase in alcohol intake is fuelling the growth of the chronic spontaneous urticaria market.

How Is the Chronic Spontaneous Urticaria Market Segmented?

The chronic spontaneous urticaria market covered in this report is segmented –

1) By Treatment: Medication, Phototherapy, Other Treatments

2) By Route Of Administration: Oral, Topical, Parenteral, Other Routes Of Administration

3) By Diagnosis: Physical Examination, Blood Test, Allergy Test, Other Diagnosis

4) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Medication: Antihistamines, Leukotriene Receptor Antagonists, Monoclonal Antibodies, Immunosuppressants, Corticosteroids (Oral and Topical)

2) By Phototherapy: UVB Phototherapy, UVA Phototherapy, Narrowband UVB Therapy

3) By Other Treatments: Alternative Therapies, Dietary Modifications, Psychotherapy (for Stress-Related Triggers)

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=16651&type=smp

Which Regions Are Driving the Next Phase of the Chronic Spontaneous Urticaria Market Growth?

North America was the largest region in the chronic spontaneous urticaria market in 2023. The regions covered in the chronic spontaneous urticaria market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Key Market Trends in the Chronic Spontaneous Urticaria Market Over the Coming Years?

Leading corporations in the chronic spontaneous urticaria market are engaging in the development of innovative next-gen Briquilimab (JSP191) to amplify the effectiveness of treatment and diminish the necessity for frequent dosing. The term ‘next-generation Briquilimab (JSP191)’ is used to denote a monoclonal antibody engineered to aim at and eliminate certain immune cells, particularly those targeting CD47, in conditions like chronic spontaneous urticaria. In November 2023, Jasper Therapeutics Inc., a clinical-stage biotech company based in the United States, declared that the first patient has received a dosage in a Phase 1b/2a clinical evaluation of Briquilimab for treating chronic spontaneous urticaria (CSU). This milestone marks a significant stride towards determining the safety and efficacy of Briquilimab, a next-gen monoclonal antibody that focuses on CD47, for treating this recurring condition of hives and itching. The research seeks to evaluate the extent to which Briquilimab can assuage symptoms and enhance the quality of life for CSU patients.

View the full report here:

https://www.thebusinessresearchcompany.com/report/chronic-spontaneous-urticaria-global-market-report

How Is the Chronic Spontaneous Urticaria Market Defined and What Are Its Core Parameters?

Chronic spontaneous urticaria (CSU) is a skin condition characterized by the recurrent appearance of hives (raised, red, itchy welts) and angioedema (swelling) lasting for more than six weeks, without an identifiable external trigger. The exact cause of CSU is often unknown, but it may involve an autoimmune component where the body’s immune system mistakenly attacks healthy skin cells. Treatment focuses on symptom management, primarily using antihistamines and, in more severe cases, other medications such as biologics.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16651

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model